Chardan Capital Issues Pessimistic Forecast for Zura Bio (NASDAQ:ZURA) Stock Price

Zura Bio (NASDAQ:ZURA) had its target price dropped by investment analysts at Chardan Capital from $12.00 to $10.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock.

Several other equities research analysts also recently commented on ZURA. Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a research note on Wednesday, December 11th. HC Wainwright restated a “neutral” rating and issued a $5.00 price target on shares of Zura Bio in a research report on Tuesday, December 24th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $15.00.

Zura Bio Trading Up 1.5 %

NASDAQ ZURA opened at $1.36 on Wednesday. Zura Bio has a twelve month low of $1.07 and a twelve month high of $6.35. The firm has a 50-day simple moving average of $1.47 and a 200 day simple moving average of $2.75.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings results on Tuesday, March 25th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.09. The business had revenue of $0.00 million for the quarter. As a group, sell-side analysts expect that Zura Bio will post -0.65 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Zura Bio

Large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its stake in Zura Bio by 70.6% in the 3rd quarter. Geode Capital Management LLC now owns 912,625 shares of the company’s stock valued at $3,706,000 after acquiring an additional 377,545 shares in the last quarter. Barclays PLC raised its holdings in shares of Zura Bio by 777.1% in the third quarter. Barclays PLC now owns 64,061 shares of the company’s stock valued at $260,000 after purchasing an additional 56,757 shares during the last quarter. Rhumbline Advisers lifted its position in shares of Zura Bio by 37.3% in the fourth quarter. Rhumbline Advisers now owns 37,657 shares of the company’s stock worth $94,000 after purchasing an additional 10,231 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in Zura Bio during the third quarter worth $71,000. Finally, Braidwell LP bought a new position in Zura Bio in the third quarter valued at $10,040,000. Institutional investors own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.